Pietro Lampertico researcher
Lampertico, Pietro.
VIAF ID: 188144782976029837448 (Personal)
Permalink: http://viaf.org/viaf/188144782976029837448
Preferred Forms
- 100 1 _ ‡a Lampertico, Pietro
-
- 100 0 _ ‡a Pietro Lampertico ‡c researcher
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Epidemiology and surveillance for hepatocellular carcinoma: New trends | |
Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C | |
Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. | |
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? | |
Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B | |
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts | |
HBV and HCV therapy. | |
HBV-related liver disease in renal insufficiency: successful antiviral therapy with entecavir | |
Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). | |
Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon | |
Hepatitis D - how is the fight against this foe going? | |
Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease | |
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting | |
How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals? | |
The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis | |
Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. | |
Indagine epidemiologica sulla patologia della tiroide in Italia 1977-1979 | |
Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. | |
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1 | |
Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. | |
Less can be more - a finite treatment approach for HBeAg-negative chronic hepatitis B. | |
Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks? | |
Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B | |
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study | |
Long-term evolution of anti-HCV-positive renal transplant recipients | |
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. | |
Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. | |
Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study | |
Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy | |
Multicentre randomised controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B/type C hepatitis after transfusion | |
Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations | |
Natural history of hepatitis C virus infection in adult renal graft recipients | |
Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B. | |
Nucleos(t)ide analogs-based chemoprevention of liver cancer in hepatitis B patients: effective, yet in search of optimization | |
Optimal management of hepatitis B virus infection - EASL Special Conference | |
Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients? | |
Oral antiviral therapy for hepatitis B: the case of besifovir, a new kid on the block with a long way to go. | |
Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice | |
Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. | |
PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history. | |
Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. | |
Persistence of hepatocellular carcinoma risk in hepatitis c patients with a response to ifn and cirrhosis regression. | |
Probability-based interpretation of liver stiffness measurement in untreated chronic hepatitis B patients. | |
Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis | |
The prognosis and management of inactive HBV carriers. | |
Prophylaxis and treatment of hepatitis B in immunocompromised patients | |
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. | |
Quarto Corso di Aggiornamento sulla Determinazione Immunoistochimica e Morfometria dei Marcatori Tumorali nelle Neoplasie Mammarie | |
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B | |
Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders | |
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis | |
Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB - Is one NUC better than the other? | |
Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues | |
Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. | |
Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. | |
The royal wedding in chronic hepatitis B: The haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapy | |
Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. | |
Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients | |
Serum type III procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic alcohol abusers | |
Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? | |
Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. | |
Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. | |
TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals | |
Tratamiento del virus de la hepatitis B: Cuáles pacientes deberían ser tratados con los análogos de nucleós(t)idos | |
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. | |
Treatment of hepatitis B: Is there still a role for interferon? | |
Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study | |
The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients. | |
The use of molecular assays in the management of viral hepatitis | |
Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a |